Global Intelligence Center

Crucell NV is currently developing the only adjuvanted flu vaccine against the influenza virus licensed for all age groups but Crucell stock hasn’t match analyst expectations showing a 20% increase since April 2009.

With two forms of influenza vaccine, BioCryst Pharma has the potential to emerge as one of the world’s top biotech companies in the fight against the swine flu. BioCryst stock has increase 450% since April 2009 reaching the best swine flu stock performed: Novavax NVAX with a 500% plus during the same period.